What We Do
Brava Diagnostics is developing acute care diagnostic products based on the MBio Diagnostics rapid testing platform. Our first applications will address unmet needs for assessment of chest pain and shortness of breath in the emergency department. Follow-on applications include diagnosis, staging and monitoring sepsis, the most expensive disease treated by hospitals.
Brava Diagnostics is assembling a world-class management team, scientists, board of directors and scientific advisory board. We are located in Boulder, Colorado. The combination of a thriving life science sector, awesome natural beauty and outstanding opportunities for outdoor activities makes Boulder a draw for top-notch talent.
Byron Hewett, Co-Founder and CEO
Byron has led healthcare and life science companies for more than 30 years, in multi-national firms, development-stage and start-up companies. His expertise is in general management, strategy, business development and sales and marketing.
From December 2013 to April 2017, he was CEO of SomaLogic, a life sciences tools company focused on biomarker discovery where he raised $240M, grew revenues from $11M-$30M and increased staff from 95 to 195. From November 2008 to August 2013, Byron served as Chairman and CEO of BioBehavioral Diagnostics a start-up medical device company with the first FDA-cleared system for the assessment of ADHD. The Company was sold to Pearson in August, 2013. From 2006 to 2008, he served as chief executive officer and a director at Immunicon Corporation (NASDAQ: IMMC), the first FDA-cleared test for circulating tumor cells (CTC) for metastatic breast, colorectal and prostate cancer. From 2004-2006 Mr. Hewett served as Chief Operating Officer and President at Immunicon. The Company was sold to Johnson & Johnson in August, 2008. From 2002-2004, he served as Senior Vice President of sales and marketing and general manager, North America for Qiagen, Inc. where he led commercial North American operations. Byron has worked in healthcare and life science companies for more than 20 years in general management, strategy formulation, business development and sales and marketing with firms including Bayer Diagnostics (VP, U.S. Branch, and VP WW Marketing, Laboratory Testing Segment), Chiron Diagnostics (President, U.S. Commercial Operations), Biocircuits Corporation, Stericycle, Inc., and Abbott Laboratories.
Byron earned a Masters in Management degree from Northwestern University's J.L. Kellogg Graduate School of Management and a Bachelor’s of Science degree from the University of Virginia's McIntire School of Commerce.
David Okrongly, Ph.D., Co-Founder and Chief Operating Officer
Dave has been a business executive and R&D leader in the diagnostics industry, ranging from start-up to multi-national companies. He brings expertise in instrument and assay development, clinical trials, regulatory affairs and operations.
From July 2013 to December 2018, Dave served as President of the OPKO Diagnostics division of OPKO Health, Inc. (NASDQ: OPK), a multi-national pharmaceutical and diagnostics company. He led the development and launch of the 4Kscore test for aggressive prostate cancer risk determination, a market leading test in the pre-biopsy space. He was also responsible for the development of the FDA-approved Claros 1 point of care analyzer utilizing fingerstick whole blood to deliver quantitative test results in 10 minutes. He served as chief operating officer of Exosome Diagnostics, Inc. from August 2011 – June 2013. Exosome Diagnostics was an early stage, venture-backed company developing molecular diagnostic tests based on proprietary technology for analyzing RNA derived from exosomes. Exosome Diafgnostics was acquired by Bio-Techne in 2018. From 2009 to 2011, he was President and CEO for Quanterix Corporation (NASDQ: QTRX), a publicly company in the life science and IVD markets He was responsible for the creating the first single molecule testing instrument, the HD-1. Dave held leadership positions with Bayer Diagnostics from 1997, including global head of R&D, and later head of the global molecular diagnostics business for Siemens Healthcare Diagnostics from 2007 to 2009.
Dave earned his PhD in Chemistry from Columbia University and a BSc with honors in Chemistry from the University of Wisconsin-Madison.
Carrie Mulherin, Co-Founder and Chief Marketing Officer
Carrie is a marketing and sales executive with extensive start-up experience and 31 product launches. Carrie brings deep experience in strategic marketing, cross-functional team management and commercialization.
Carrie was CEO of Focus Marketing, an independent consulting agency, from November 2017. From August 2014 to October 2017, Carrie served as VP Diagnostics at SomaLogic. From 2009 to 2014, she was VP of Marketing and Sales for BioBDx/Pearson, a start-up medical device company. She served as Director of Marketing at OraSure Technologies in 2008-2009, managing the infectious disease rapid assay franchise. From 2002 to 2008, Carrie served as Vice President of Marketing and Sales at Immunicon Corporation, a development stage company in the liquid biopsy/cancer market. From 2000 to 2002, she worked at start-up diagnostics company, ThauMDx, which developed instruments and multiplex assays for point-of-care settings, including cardiac markers. From 1997 to 2000, she was Vice President of Sales and Marketing for Intracel Corporation. Carrie brings more than 20 years of sales, marketing and business development experience in the diagnostics, medical device, CRO and pharmaceutical industries.
Carrie earned a bachelor’s degree in molecular biology and biochemical sciences from Princeton University and an MBA in marketing from the University of Scranton.
Scientific Advisory Board
|Fred Apple, PhD||Hennepin Co Medical Center, Hennepin Healthcare Research Institute (HHRI)||Co-Director Clinical & Forensic Toxicology Laboratory. Principal Investigator, Cardiac Biomarkers Trials Laboratory. Professor, Laboratory Medicine & Pathology, University of Minnesota.|
|Judd Hollander, MD||Thomas Jefferson University||SVP of Healthcare Delivery Innovation. Associate Dean for Strategic Health Initiatives. Vice Chair of Finance and Healthcare Enterprises, Dept of Emergency Medicine.|
|Allan Jaffe, MD||Mayo Clinic||Chair of the Division of Clinical Core Laboratory Services in the Department of Laboratory Medicine and Pathology|
|Frank Peacock, MD||Baylor College of Medicine||Associate Chair of Emergency Medicine. Founding member/ past President and Chief Medical Officer of the Accreditation Management Board of the American College of Cardiology.|
|Nelson Trujillo, MD||Boulder Community Health||Interventional Cardiologist|
|Alan Wu, PhD||UCSF||Professor, Laboratory Medicine. Co-core lab director, Zuckerberg San Francisco General Hospital.|
|Richard Zane, MD||University of Colorado School of Medicine||Chair of the Department of Emergency Medicine. Chief Innovation Officer for UCHealth|
Board of Directors
Robert J. Silverman, Chairman of the Board and Independent Director
Robert J. Silverman is the Board Chairman for Brava Diagnostics. Bob currently serves in a Board and Advisory capacity to a portfolio of companies including MBio Diagnostics, Kiyatec Inc., Lophius Biosciences GmbH, Pathovax LLC and Gilde Healthcare Venture Partners.
He served as the CEO of mtm laboratories AG, an in-vitro diagnostics company that developed and commercialized a portfolio of products for the early detection and diagnosis of cervical cancer. Bob was instrumental in raising capital and building mtm laboratories into a global, fully-integrated commercial business. He led the company to a $240 Million exit to Roche Diagnostics. Prior to leading mtm laboratories, he held senior executive positions at Viacell, Cytyc Corporation, Pasteur Merieux and Abbott Laboratories Pharmaceuticals.
He earned his Master’s Degree in Marketing and Finance from the Kellogg Graduate School of Management at Northwestern University. Bob received his B.S. in Pharmacy from the University of Michigan.
Byron Hewett, Chief Executive Officer, Brava Diagnostics
Christopher J. Myatt, Ph.D. Chief Executive Officer, MBio Diagnostics
Dr. Myatt is the founder and CEO of MBio Diagnostics, Inc. He is an entrepreneur with a proven track record for building technology companies, securing patents and licensing technology, raising funding, establishing commercial operations, and leading through growth. Prior to MBio Diagnostics, Chris successfully founded and led Precision Photonics Corporation, a successful laser and optical technology supplier that is now a division of IDEX. Trained as a physicist and measurement scientist, Chris invented and developed multiple technologies that formed the basis of his companies.
Chris earned a B.S. in Physics and a B.A. in Mathematics at Southern Methodist University. Chris also earned a Ph.D. in Atomic Physics at the University of Colorado. He studied Bose-Einstein Condensation (BEC) under Carl Wieman (Nobel Prize, 2001), helping to create the first BEC condensate in the Wieman lab. He also studied quantum information under David Wineland (Nobel Prize, 2012) as a National Research Council (NRC) Postdoctoral Fellow at the National Institute of Standards and Technology (NIST) in Boulder.
Learn More about the Team
Read short biographies on the executive team and Board.
Download our Fact Sheet
Download a 2-page summary about our strategy.
Schedule a Meeting
Brava is currently raising seed financing. Let's talk!